Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M141,549Revenue $M39,498Net Margin (%)11.3Altman Z-Score2.7
Enterprise Value $M156,219EPS $1.6Operating Margin %17.5Piotroski F-Score6
P/E(ttm)13.2Beneish M-Score-2.6Pre-tax Margin (%)13.7Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %5.4Quick Ratio1.3Cash flow > EarningsY
Price/Sales4.85-y EBITDA Growth Rate %4.0Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow29.6y-y EBITDA Growth Rate %-8.2ROA % (ttm)5.2Higher Current Ratio y-yY
Dividend Yield %3.7PEG3.3ROE % (ttm)11.4Less Shares Outstanding y-yY
Payout Ratio %48.0Shares Outstanding M2,794ROIC % (ttm)12.3Gross Margin Increase y-yY

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKT Rowe Price Equity Income Fund 2015-12-31 Reduce-0.21%$49.47 - $55.53
($52.89)
$ 49.38-7%Reduce -14.63%5,610,000
MRKJames Barrow 2015-12-31 Add0.12%$49.47 - $55.53
($52.9)
$ 49.38-7%Add 5.86%26,655,176
MRKVanguard Health Care Fund 2015-12-31 Add0.08%$49.47 - $55.53
($52.9)
$ 49.38-7%Add 1.47%50,476,700
MRKKen Fisher 2015-12-31 Add0.01%$49.47 - $55.53
($52.89)
$ 49.38-7%Add 0.89%6,822,070
MRKMario Gabelli 2015-12-31 Reduce$49.47 - $55.53
($52.9)
$ 49.38-7%Reduce -2.17%139,615
MRKVanguard Health Care Fund 2015-09-30 Add0.43%$48.42 - $59.71
($55.67)
$ 49.38-11%Add 8.73%49,743,388
MRKKahn Brothers 2015-09-30 Reduce-0.1%$48.42 - $59.71
($55.67)
$ 49.38-11%Reduce -1.02%1,006,208
MRKDavid Dreman 2015-09-30 Sold Out -0.05%$48.42 - $59.71
($55.67)
$ 49.38-11%Sold Out0
MRKJames Barrow 2015-09-30 Reduce-0.04%$48.42 - $59.71
($55.67)
$ 49.38-11%Reduce -1.80%25,179,076
MRKCharles Brandes 2015-09-30 Reduce-0.02%$48.42 - $59.71
($55.67)
$ 49.38-11%Reduce -0.90%2,791,984
MRKT Rowe Price Equity Income Fund 2015-09-30 Reduce-0.01%$48.42 - $59.71
($55.67)
$ 49.38-11%Reduce -0.82%6,571,200
MRKKen Fisher 2015-09-30 Reduce-0.01%$48.42 - $59.71
($55.67)
$ 49.38-11%Reduce -1.09%6,761,706
MRKMario Gabelli 2015-09-30 Reduce$48.42 - $59.71
($55.67)
$ 49.38-11%Reduce -3.92%142,715
MRKRuane Cunniff 2015-09-30 Add$48.42 - $59.71
($55.67)
$ 49.38-11%Add 4.39%4,994
MRKDodge & Cox 2015-09-30 Reduce$48.42 - $59.71
($55.67)
$ 49.38-11%Reduce -0.39%24,585,258
MRKNWQ Managers 2015-09-30 Reduce$48.42 - $59.71
($55.67)
$ 49.38-11%Reduce -5.36%69,835
MRKJoel Greenblatt 2015-09-30 Buy $48.42 - $59.71
($55.67)
$ 49.38-11%New holding5,844
MRKVanguard Health Care Fund 2015-06-30 Add0.65%$56.73 - $60.89
($58.76)
$ 49.38-16%Add 14.09%45,748,498
MRKCharles Brandes 2015-06-30 Add0.44%$56.73 - $60.89
($58.76)
$ 49.38-16%Add 26.81%2,817,473
MRKJoel Greenblatt 2015-06-30 Sold Out -0.3%$56.73 - $60.89
($58.76)
$ 49.38-16%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
WEEKS WENDELL PDirector 2015-11-04Sell5,000$55.53-11.08view
AMBROSE ADELE DSr.V-P & Chief Comuns Officer 2015-10-29Sell37,313$55.08-10.35view
FRAZIER KENNETH CChairman, President & CEO 2015-10-29Sell18,666$54.69-9.71view
WENDELL PETER CDirector 2015-10-28Sell5,000$54.85-9.97view
Golestani ClarkEVP & Chief Info Officer 2015-07-31Sell31,831$59.09-16.43view
Schechter Adam HEVP & Pres-Global Human Health 2015-05-11Sell10,634$60.44-18.3view
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy 2015-05-08Sell38,368$60.99-19.04view
Kuhlik Bruce NExe V-P & Gen Counsel 2015-05-04Sell56,064$60.2-17.97view
Holston Michael JEVP, Legal 2015-04-29Sell95,624$59.84-17.48view
Kuhlik Bruce NExe V-P & Gen Counsel 2015-04-29Sell156,902$59.82-17.45view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

    News about MRK:

    Articles On GuruFocus.com
    Richard Snow Makes Huge Increases in Big-Name Stocks Jan 08 2016 
    5 Top Stocks of the Outperforming Vanguard Health Care Fund Dec 28 2015 
    5 Guru Picks in Volatile Biotech Industry Dec 23 2015 
    Kahn Brothers' Largest Sales During 3rd Quarter Dec 22 2015 
    Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
    Richard Snow Invests in Familiar Names in 3rd Quarter Nov 13 2015 
    Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser? Nov 12 2015 
    Pfizer to Create a New Pharmaceutical Colossus Nov 05 2015 
    Vanguard Health Care Fund Buys Biogen and Mylan, Cuts Pfizer Nov 02 2015 
    Charles Brandes' Most Weighted Trades in Q2 2015 Sep 30 2015 

    More From Other Websites
    ImmunoGen/Merck Collaborate for Ovarian Cancer Study Feb 05 2016
    Merck & Co., Inc. Earnings Analysis: 2015 By the Numbers Feb 05 2016
    FDA staff supports Celltrion's biosimilar Remicade Feb 05 2016
    String of Q4 Earnings Beat Fails to Revive Pharma ETFs Feb 05 2016
    FDA reviewers support Celltrion's biosimilar Remicade Feb 05 2016
    It’s Time to Buy This Biotech Gem Feb 04 2016
    Here's why ImmunoGen's CEO is psyched for combo tests with Keytruda Feb 04 2016
    8:02 am Merck: FDA approves a sNDA for single-dose EMEND for injection in combination with other... Feb 04 2016
    FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination... Feb 04 2016
    Emerging Situations, Growth Study - Analyst Notes on Apple, Merck & Co, Wal Mart Stores and Home... Feb 04 2016
    What Were the Overall Trends in Large-Cap Mutual Funds Last Year? Feb 04 2016
    Merck Stock Slides As Q4 Revenue, Guidance Miss Expectations Feb 03 2016
    Merck and Chipotle are big market movers Feb 03 2016
    Edited Transcript of MRK earnings conference call or presentation 3-Feb-16 1:00pm GMT Feb 03 2016
    [$$] Merck Revenue and Profit Fall Feb 03 2016
    Merck Drops On Light Q4 Sales, Full-Year Guidance Feb 03 2016
    Merck: A Leg Up In The Cancer Drug Race Feb 03 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK